Published September 30, 2019 | Version v1
Dataset Open

Large-scale purification of Q23 HTT from Sf9 2019/09/30

  • 1. Structural Genomics Consortium, University of Toronto


Project: Biophysical investigation of purified HTT protein samples

Experiment: Large-scale purification of Q23 HTT from Sf9 

Date completed:­ 2019/09/30

Rationale: HTT samples are to be purified from different systems for subsequent biophysical and structural studies. 


Dr. Harding is the recipient of the Huntington's Disease Society of America Berman Topper Career Development Fellowship which funds and supports this research, in addition to generous funding from the CHDI Foundation and the Huntington Society of Canada. The SGC is a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada through Ontario Genomics Institute [OGI-055], Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant no. 115766], Janssen, Merck KGaA, Darmstadt, Germany, MSD, Novartis Pharma AG, Ontario Ministry of Research, Innovation and Science (MRIS), Pfizer, São Paulo Research Foundation-FAPESP, Takeda, and Wellcome.


Large-scale purification of Q23 HTT from Sf9 20190930.pdf

Files (428.7 kB)